Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Cytarabine 48Cyclophosphamide 41Etoposide 34fludarabine phosphate 26Filgrastim 26Peripheral Blood Stem Cell Transplantation 25Radiotherapy 24Daunorubicin 24Vincristine 20Methotrexate 20Busulfan 18Mitoxantrone 15Idarubicin 15Doxorubicin 13Dexamethasone 13Rituximab 12Asparaginase 12Prednisone 11Mercaptopurine 11Cyclosporine 11Thioguanine 9Leucovorin 9Ifosfamide 9Antilymphocyte Serum 9laromustine 8Prednisolone 8fludarabine 7Methylprednisolone 7Interferon-alpha 7aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia × Furosemide × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡